Evolution of Antibiotic Multiresistance in Escherichia Coli and Klebsiella Pneumoniae Isolates from Urinary Tract Infections: A 12-year Analysis (2003-2014)
Overview
Affiliations
Introduction: The aim of this study was to identify multi-drug resistance (MDR) in the main enterobacteriaceae implicated in urinary tract infections (Escherichia coli and Klebsiella pneumoniae) from both, community and hospitalized patients and to analyze the evolution over a 12-year period.
Methods: Microb Dynamic software was used to analyze the microbiology laboratory database and a chi square test was applied to compare differences in group proportions and to determine the linear trend over 12 years in three different periods: 2003-2006, 2007-2010, 2011-2014. We chose amoxicillin, gentamicin, ciprofloxacin and trimethoprim-sulphamethoxazole as MDR markers.
Results: A total of 39,980 positive urine samples were analyzed, 34,564 (3786 from hospitalized patients and 30,778 from non-hospitalized patients) E. coli isolates, and 5,422 (774 from hospitalized patients and 4,648 from non-hospitalized patients) K. pneumoniae isolates. The prevalence of UTI due to MDR E. coli and MDR K. pneumoniae significantly increased in the period studied, both in hospitalized and outpatients. A higher percentage of MDR E. coli (5.89% in 2007-2010 versus 8.18% in 2011-2014) and MDR K. pneumoniae (2.38% in 2007-2010 versus 9.35% in 2011-2014) was evident and maintained constant over time in hospitalized patients in comparison to non-hospitalized ones. Infection due to MDR ESBL-producing E. coli and K. pneumoniae increased significantly during the last 8 years in both, hospitalized (20% versus 38% and 66.8% versus 82.6%, respectively) and non-hospitalized patients (18.2% versus 23.6% and 51% versus 74.6%, respectively).
Conclusions: This study includes data of a large sample size of urinary strains isolated over a 12 year period and demonstrates that MDR is an increasing phenomenon of particular importance in the main UTI-causing species.
Maveke S, Aboge G, Kanja L, Mainga A, Gachau N, Muchira B Int J Microbiol. 2024; 2024:7463899.
PMID: 38384586 PMC: 10881238. DOI: 10.1155/2024/7463899.
Jalil M, Al Atbee M J Clin Lab Anal. 2022; 36(9):e24619.
PMID: 35870190 PMC: 9459318. DOI: 10.1002/jcla.24619.
A Descriptive Analysis of Urinary ESBL-Producing- in Cerdanya Hospital.
Gaviria L, Montsant L, Azuaje C, Gonzalez-Diaz A, Horcajada J, Limon E Microorganisms. 2022; 10(3).
PMID: 35336064 PMC: 8953596. DOI: 10.3390/microorganisms10030488.
Romero Nieto M, Maestre Verdu S, Gil V, Perez Barba C, Rico J, Pascual Perez R J Clin Med. 2021; 10(21).
PMID: 34768712 PMC: 8584794. DOI: 10.3390/jcm10215192.
Poletajew S, Pawlik K, Bonder-Nowicka A, Pakuszewski A, Nyk L, Kryst P Antibiotics (Basel). 2021; 10(10).
PMID: 34680812 PMC: 8532629. DOI: 10.3390/antibiotics10101232.